Staff Profile

I lead a translational gastroenterology research group within the Faculty of Medical Sciences and am a Consultant Gastroenterologist at the Newcastle Hospitals with a specialist interest in Inflammatory Bowel Disease (IBD; encompassing Crohn’s disease and ulcerative colitis). I lead an integrated research programme in IBD precision medicine spanning the translational spectrum from mucosal immunology and microbiology, to clinical trials, health economics and clinical quality improvement. My laboratory group investigate the intestinal immune system, how this maintains health or can drive inflammation, and how our immune system interacts with, and is shaped by gut microbiota (bacteria, viruses and fungi) and diet. Having previously undertaken a Wellcome Trust Clinical Fellowship in Translational Medicine and Therapeutics, I have worked within and continue to collaborate with the international biotechnology sector to best translate laboratory findings into patient benefit.

I am the Chief Investigator for the national IBD-RESPONSE and CD-metaRESPONSE studies: Defining predictors of responsiveness to advanced therapies in Crohn’s disease and ulcerative colitis, funded by the Medical Research Council and The Helmsley Charitable Trust. This programme aims to develop a predictive model of response to immune modifying therapy in IBD based on human immune, gut microbiome, metabolomic and dietary data. I am Clinical Chief Investigator for Open-IBD: Longitudinal multi-omics inception study of Crohn's disease and ulcerative colitis, funded by Open Targets and the Wellcome Sanger Institute. I am also Deputy IBD lead for the EU funded programme, IDEA-FAST: Identifying Digital Endpoints to Assess Fatigue, Sleep and activities of daily living in neurodegenerative disorders and immune-mediated inflammatory diseases. In 2023, I was awarded the Sir Francis Avery Jones medal for research excellence from the British Society of Gastroenterology and have been a previous recipient of the President's medal for outstanding contribution to the Society. In 2023 I was awarded a Rising Star by United European Gastroenterology.

I am the lead author of the British Society of Gastroenterology guidelines for the diagnosis and management of IBD and the co-lead author for the joint British Society of Gastroenterology and British Society of Paediatric Gastroenterology Hepatology and Nutrition guidelines for diagnosis and care coordination of monogenic IBD. I work closely with the patient representative body Crohn's & Colitis UK and sit on the Steering Committee of IBD UK to contribute to national qualitative improvement research and clinical implementation in IBD care including development of the UK IBD Standards and subsequent national Benchmarking of IBD Services across all four nations of the UK. From 2021-2024 I was the Secretary of the British Society of Gastroenterology IBD Section. I provide expert advice on policy to several national bodies including NHS England, NICE and the King’s Fund.

I undertake clinical duties within the gastroenterology department of the Newcastle upon Tyne Hospitals NHS Foundation Trust. Details of my clinical activity can be found at the Newcastle upon Tyne Hospitals website.

The overarching purpose of my research programme is to improve the lives of patients impacted by gastrointestinal inflammation. I study ulcerative colitis and Crohn’s disease, the two principal forms of inflammatory bowel disease (IBD), and several other inflammatory conditions of the gut including necrotising enterocolitis, primary immunodeficiency, immune-oncology mediated colitis and cancer. The aim of my laboratory work is to investigate aspects of the human immune system and microbes that reside within the gut to contribute to efforts in precision medicine; a concept that requires detailed immune understanding in order to provide the right drug, to the right patient, at the right time. My research group study cellular and microbial processes in human health and during inflammation to better understand how these mechanisms may trigger or perpetuate disease, how they differ between individuals and whether there are biological signatures that may be associated with aspects of disease severity or response to therapy. My group study aberrant innate and adaptive responses in leukocytes (white blood cells), epithelial cells, and also gut microbes (bacteria, viruses and fungi) to unravel how they impact human cellular behaviour. This type of research is essential in order to develop new and improved treatments, or to better use existing therapies.

Within the NHS, I work as part of the inflammatory bowel disease clinical research team in the Newcastle Hospitals in collaboration with patients to deliver an excellent track record of recruitment to clinical trials of new treatments in IBD and observational cohort studies. Newcastle patients have also provided strong support for the UK contribution to large-scale genetic discovery studies in both ulcerative colitis and Crohn’s disease.

Further details of my work can be found on social media, awarded grants can be found at ORCiD and publications at Google Scholar.

More information about the IBD-RESPONSE and CD-metaRESPONSE programmes can be found at the IBD-RESPONSE website, or on social media.

I believe teaching is of fundamental importance to develop outstanding future researchers and healthcare professionals, plus is essential to share knowledge and promote best practice amongst established scientists and clinicians. I lecture as part of the Biomedical Sciences (BSc) and Medicine undergraduate (MBBS) degree courses at Newcastle University on subjects including gastroenterology, immunology, the gut microbiome and the ethics of research. I also take part in regular clinical classroom and bedside teaching of medical students within the Newcastle Hospitals.

I frequently deliver national and international state of the art educational presentations and convene conferences regarding best clinical practice, cutting-edge research and academic leadership. During 2020-2024 this has included lectures at the Royal College of Physicians of London, Royal College of Physicians of Edinburgh, Royal College of Physicians & Surgeons of Glasgow, British Society of Gastroenterology, Royal College of General Practitioners, Scottish Society of Paediatric Gastroenterology Hepatology and Nutrition, British Society of Rheumatology, European Crohn's & Colitis Organisation, United European Gastroenterology and International Organization for the Study of IBD.

• Articles

  • Gault A, Hogarth L, Williams KC, Greystoke A, Rajan N, Speight A, Lamb CA, Bridgewood A, Brown-Schofield LJ, Rayner F, Isaacs JD, Nsengimana J, Stewart CJ, Anderson AE, Plummer R, Pratt AG. Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study. BMC Cancer 2024, 24(1), 733.
  • Lamb CA, Titterton C, Banerjee R, Gomberg A, Rubin DT, Hart AL. Inflammatory bowel disease has no borders: engaging patients as partners to deliver global, equitable and holistic health care. The Lancet 2024, 404(10451), 414-417.
  • Selinger CP, Bottle A, Lamb CA, Ainley R, Wakeman R, Hawthorne B. Evaluation of emergency hospital admissions for inflammatory bowel disease as a possible marker of quality of care of British IBD inflammatory bowel disease units. Frontline Gastroenterology 2024, epub ahead of print.
  • Wyatt NJ, Watson H, Anderson CA, Kennedy NA, Raine T, Ahmad T, Allerton D, Bardgett M, Clark E, Clewes D, Martin CC, Doona M, Doyle JA, Frith K, Hancock H, Hart A, Hildreth V, Irving PM, Iqbal S, Kennedy C, King A, Lawrence S, Lees CW, Lees R, Letchford L, Liddle T, Lindsay JO, Maier RH, Mansfield JC, Marchesi JR, McGregor N, McIntyre RE, Ostermayer J, Osunnuyi T, Powell N, Prescott NJ, Satsangi J, Sharma S, Shrestha T, Speight A, Strickland M, Wason JMS, Whelan K, Wood R, Young GR, Zhang X, Parkes M, Stewart CJ, Jostins-Dean L, Lamb CA. Defining predictors of responsiveness to advanced therapies in Crohn’s disease and ulcerative colitis: Protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine. BMJ Open 2024, 14(4).
  • Alexander JL, Wyatt NJ, Camuzeaux SSM, Chekmeneva E, Jimenez B, Sands CJ, Fuller H, Ahmad T, Doyle JA, Hart A, Irving PM, Kennedy NA, Lees CW, Lindsay JO, McIntyre RE, Parkes M, Prescott N, Raine T, Satsangi J, Speight RA, Jostins-Dean L, Powell N, Marchesi JR, Stewart CJ, Lamb CA. Considerations for peripheral blood transport and storage during large-scale multicentre metabolome research. Gut 2024, 73(2), 379-383.
  • Kapizioni C, Desoki R, Lam D, Balendran K, Al-Sulais E, Subramanian S, Rimmer JE, De La Revilla Negro J, Pavey H, Pele L, Brooks J, Moran GW, Irving PM, Limdi JK, Lamb CA, UK IBD BioResource Investigators, Parkes M, Raine T. Biologic therapy for inflammatory bowel disease: Real-world comparative effectiveness and impact of drug sequencing in 13,222 patients within the UK IBD BioResource. Journal of Crohn's and Colitis 2024, 18(6), 790–800.
  • Lees CW, Ahmad A, Lamb CA, Powell N, Din S, Cooney R, Kennedy NA, Ainley R, Wakeman R, Selinger CP. Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity. Gut 2023, 72(2), 410-412.
  • Louis E, Resche-Rigon M, Laharie D, Satsangi J, Ding N, Siegmund B, D'Haens G, Picon L, Bossuyt P, Vuitton L, Irving P, Viennot S, Lamb CA, Pollok R, Baert F, Nachury M, Fumery M, Gilletta C, Almer S, Ben-Horin S, Bouhnik Y, Colombel J-F, Hertervig E, GETAID and the SPARE-Biocycle research group. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial. The Lancet Gastroenterology and Hepatology 2023, 8(3), 215-227.
  • Kennedy NA, Janjua M, Chanchlani N, Lin S, Bewshea C, Nice R, McDonald TJ, Auckland C, Harries LW, Davies M, Michell S, Kok KB, Lamb CA, Smith PJ, Hart AL, Pollok RCG, Lees CW, Boyton RJ, Altmann DM, Sebastian S, Powell N, Goodhand JR, Ahmad T. Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic. Gut 2023, 72(2), 295-305.
  • Baillie S, Limdi JK, Bassi A, Fraser A, Parkes G, Scott G, Raine T, Lamb CA, Kennedy NA, Fumis N, Smith MA, Nicolaou A, Emms H, Wye J, Lehmann A, Carbery I, Goodhand J, Lees R, Beshyah W, Luthra P, Pollok R, Selinger C. Opioid use and associated factors in 1676 patients with inflammatory bowel disease: a multicentre quality improvement project. Frontline Gastroenterology 2023, 14(6), 497-504.
  • Liu Z, Le K, Zhou X, Alexander JL, Lin S, Bewshea C, Chanchlani N, Nice R, McDonald TJ, Lamb CA, Sebastian S, Kok K, Lees CW, Hart AL, Pollok RC, Boyton RJ, Altmann DM, Pollock KM, Goodhand JR, Kennedy NA, Ahmad T, Powell N. Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with inflammatory bowel disease after three doses of COVID-19 vaccine (CLARITY IBD): a prospective multicentre cohort study (CLARITY). The Lancet Gastroenterology and Hepatology 2023, 8(2), 145-156.
  • Kammermeier J, Lamb CA, Jones KDJ, Anderson CA, Baple EL, Bolton C, Braggins H, Coulter TI, Gilmour KC, Gregory V, Hambleton S, Hartley D, Hawthorne AB, Hearn S, Laurence A, Parkes M, Russell RK, Speight RA, Travis S, Wilson DC, Uhlig HH. Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutrition. The Lancet Gastroenterology and Hepatology 2023, 8(3), 271-286.
  • Quraishi MN, Dobson E, Ainley R, Din S, Wakeman R, Cummings F, Sebastian S, Bloom S, Limdi JK, Dhar A, Speight RA, Bodger K, Kennedy NA, Lamb CA, Arnott I, Selinger CP. Establishing key performance indicators for inflammatory bowel disease in the UK. Frontline Gastroenterology 2023, 14(5), 407-414.
  • Williams KM, Lamidi S, Coe PO, Bordeianou LG, Hart AL, Hind D, Lindsay JO, Lobo AJ, Myrelid P, Raine T, Sebastian S, Fearnhead NS, Lee MJ, Adams K, Almer S, Ananthakrishnan A, Bethune RM, Block M, Brown SR, Cirocco WC, Cooney R, Davies J, Atici SD, Dhar A, Din S, Drobne D, Espin-Basany E, Evans JP, Fleshner PR, Folkesson J, Fraser A, Graf W, Hahnloser D, Hager JH, Hancock L, Hanzel J, Hargest R, Hedin CRH, Hill J, Ihle C, Jongen J, Kader R, Karmiris K, Katsanos KH, Keller DS, Kopylov U, Koutrabakis IE, Lamb CA, Landerholm K, Lee GC, Litta F, Limdi JK, Lopes EW, Madoff RD, Martin ST, Martin-Perez B, Michalopoulos G, Millan M, Munch A, Nakov R, Noor NM, Oresland T, Paquette IM, Pellino G, Perra T, Porcu A, Roslani AC, Samaan MA, Sebepos-Rogers GM, Segal JP, deSilva S, Soderholm M, Spinelli A, Speight A, Steinhagen RM, Stenstrom P, Tsimogiannis KE, Varma MG, Verma AM, Verstockt B, Warden C, Yassin N, Zawadzki A, Carr P, Devlin B, Mannick S, Avery P, Gecse KB, Goren I, Hellstrom PM, Kotze PG, McWhirter D, Naik AS, Sammour T, Selinger CP, Stein SL, Torres J, Wexner SD, Younge LC. Development of a core descriptor set for Crohn's anal fistula. Colorectal Disease 2023, 25(4), 695-706.
  • Kabir M, Thomas-Gibson S, Tozer PJ, Warusavitarne J, Faiz O, Hart A, Allison L, Acheson AG, Atici SD, Avery P, Brar M, Carvello M, Choy MC, Dart RJ, Davies J, Dhar A, Din S, Hayee B, Kandiah K, Katsanos KH, Lamb CA, Limdi JK, Lovegrove RE, Myrelid P, Noor N, Papaconstantinou I, Petrova D, Pavlidis P, Pinkney T, Proud D, Radford S, Rao R, Sebastian S, Segal JP, Selinger C, Spinelli A, Thomas K, Wolthuis A, Wilson A. DECIDE: Delphi Expert Consensus Statement on Inflammatory Bowel Disease Dysplasia Shared Management Decision-Making. Journal of Crohn's & Colitis 2023, 17(10), 1652–1671.
  • Dart RJ, Zlatareva I, Vantourout P, Theodoridis E, Amar A, Kannambath S, East P, Recaldin T, Mansfield JC, Lamb CA, Parkes M, Irving PM, Prescott NJ, Hayday AC. Conserved γδ T cell selection by BTNL proteins limits progression of human inflammatory bowel disease. Science 2023, 381(6663), eadh0301.
  • Churchhouse AMD, Moffat VEL, Selinger CP, Lamb CA, Thornton MJ, Penman I, Din S. British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance. Gut 2023, 72(9), 1631-1634.
  • Saifuddin A, Kent AJ, Mehta SJ, Hicks LC, Gonzalez HA, Segal JP, Brookes MJ, Subramanian S, Bhala N, Conley TE, Patel KV, Lamb CA, Walker GJ, Kennedy NA, Sebastian S, Abdale S, Abbesi A, Abusrewil A, Aghimien P, Ahmed S, Ali A, Ali A, Alkhouri J, Allen P, Al-Rifaie A, Appleby R, Arasaradnam R, Arebi N, Arms-Williams B, Ashraf M, Andrea A, Avades T, Ayubi H, Baillie S, Balarajah S, Bancil A, Basit A, Bayati M, Bell A, Berry A, Bhala N, Bhat S, Bhattacharyya J, Bishop S, Blackmore L, Bond A, Borg-Bartolo S, Botwright E, Bouri S, Boyle S, Bradley N, Brailsford F, Brennan E, Britton D, Brooks M, Brown C, Butcher R, Butterworth J, Campbell R, Campbell R, Campbell I, Carr R, Carter J, Cartlidge P, Chandy R, Chatten K, Chaudhary R, Chee D, Chessbrough J, Churchhouse A, Clough J, Cole A, Conley T, Cook J, Cooney R, Cotton S, Critchlow T, Cuison F, Curran C, Darie A-M, Dart R, Davwar P, Dawa KK, Dhar A, Din S, Diong KL, Disney B, Dooks E, Downey L, D'Souza A, Dyall L, Elias M, Felwick R, Finegan M, Flanagan P, Fofaria R, Fong S, Fox R, Fraser A, Frunza C, Ghodeif A, Ghosh N, Gilroy L, Gonzalez HA, Good L, Gordon J, Grasso N, Gueroult A, Gulliver J, Guthrie S, Gwiggner M, Hanna M, Harlow C, Harrison W, Hart A, Hawthorne B, Hicks L, Hooper P, Howard W, Hussain N, Hutton T, Htun AM, Irving P, Jagdish R, Javed A, Javed A, Jayasooriya N, Johnson M, Johnston E, Jones G-R, Kanagasundaram C, Karagkouni F, Kemp K, Kennedy N, Kent A, Khalil H, Khan N, Khan Z, Khasawneh M, King A, Kirkham B, Kirkham F, Kokwaro F, Korani M, Koumoutsos I, Kumar A, Kuzhiyanjal AJK, Lakeland M, Lamb C, Laverick S, Lees C, Levell E, Levison S, Lim S, Lim Y-H, Limdi J, Lindsay J, Lisle J, Lobo A, Luber R, Lucacui L, Lyne H, MacDonald J, Mahalingam A, Mahgoub S, Malakar R, Marley F, Mason J, Masri A, Mazhar Z, McCaughan H, McCort T, McCulloch A, McIlwaine S, Meah N, Mebarek L, Mehta S, Mendall M, Mir N, Moffatt V, Moran G, Morris L, Morrison G, Morrison G, Mulligan R, Murray C, Murray J, Myers S, Naeck-Boolauky P, Naranjo A, Navaratnam J, Naylor D, Nixon E, Nixon K, Nolan J, Olabintan O, San EOM, Owen H, Palmer-Jones C, Patel K, Peddada K, Pee L, Peerally M, Perkins R, Phillips F, Pohl K, Pollok R, Powell N, Qayyum F, Quarashi M, Quraishi MN, Radcliffe E, Radford S, Rahmany S, Ramadan H, Ramadas A, Reddington A, Riggott C, Riley T, Rimmer P, Ritchie S, Rosiou K, Rowland S, Sabine J, Saifuddin A, Sarwar S, Sasegbon A, Saunders J, Sebastian S, Sebepos-Rogers G, Seenan JP, Segal J, Selinger C, Serna S, Sethi S, Shale M, Shenderey R, Shenoy A, Sherifat Y, Sheth R, Siakavellas S, Sikafi R, Singh A, Singh S, Singh U, Sivaji G, Smith P, Speight A, Spence A, Stansfield C, Steed H, Subramanian S, Suseehran K, Tabuso M, Taucius D, Taylor J, Thakor A, Tham T, Townsend G, Townsend T, Troth T, Tunney R, Turner K, Umar N, Vakeeswarasarma V, Verma A, Walker G, Wallace H, Walton H, Wang B, Warner E, Watson C, Wen S, Widlak M, Williams M, Woods A, Younge L, Zafar M. Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study. Alimentary Pharmacology and Therapeutics 2022, 56(10), 1460-1474.
  • Beck LC, Masi AC, Young GR, Vatanen T, Lamb CA, Smith R, Coxhead J, Butler A, Marsland BJ, Embleton ND, Berrington JE, Stewart CJ. Strain-specific impacts of probiotics are a significant driver of gut microbiome development in very preterm infants. Nature Microbiology 2022, 7, 1525-1535.
  • Granger CL, Lamb CA, Embleton ND, Beck LC, Masi AC, Palmer JM, Stewart CJ, Berrington JE. sIgA in preterm infants: determination of normal values in breast milk and stool. Pediatric Research 2022, 92(4), 979-986.
  • Houghton D, Ng YS, Jackson MA, Stefanetti R, Hynd P, Aogáin MM, Stewart CJ, Lamb CA, Bright A, Feeney C, Newman J, Turnbull DM, McFarland R, Blain AP, Gorman GS. Phase II feasibility study of the efficacy, tolerability and impact on the gut microbiome of a low residue (fibre) diet in adult patients with mitochondrial disease. Gastro Hep Advances 2022, 1(4), 666-677.
  • Young GR, Berrington JE, Cummings S, Dorling J, Ewer AK, Frau A, Lett L, Probert C, Juszczak E, Kirby J, Beck L, Renwick VL, Lamb CA, Lanyon C, McGuire W, Stewart CJ, Embleton ND. Mechanisms affecting the gut of preterm infants in enteral feeding trials: a nested cohort within a randomised controlled trial of lactoferrin. Archives of Disease in Childhood 2022, 108(3), 272-279.
  • Sazonovs A, Stevens CR, Venkataraman GR, Yuan K, Avila B, Abreu MT, Ahmad T, Allez M, Ananthakrishnan AN, Atzmon G, Baras A, Barrett JC, Barzilai N, Beaugerie L, Beecham A, Bernstein CN, Bitton A, Bokemeyer B, Chan A, Chung D, Cleynen I, Cosnes J, Cutler DJ, Daly A, Damas OM, Datta LW, Dawany N, Devoto M, Dodge S, Ellinghaus E, Fachal L, Farkkila M, Faubion W, Ferreira M, Franchimont D, Gabriel SB, Ge T, Georges M, Gettler K, Giri M, Glaser B, Goerg S, Goyette P, Graham D, Hamalainen E, Haritunians T, Heap GA, Hiltunen M, Hoeppner M, Horowitz JE, Irving P, Iyer V, Jalas C, Kelsen J, Khalili H, Kirschner BS, Kontula K, Koskela JT, Kugathasan S, Kupcinskas J, Lamb CA, Laudes M, Levesque C, Levine AP, Lewis JD, Liefferinckx C, Loescher BS, Louis E, Mansfield J, May S, McCauley JL, Mengesha E, Mni M, Moayyedi P, Moran CJ, Newberry RD, OCharoen S, Okou DT, Oldenburg B, Ostrer H, Palotie A, Paquette J, Pekow J, Peter I, Pierik MJ, Ponsioen CY, Pontikos N, Prescott N, Pulver AE, Rahmouni S, Rice DL, Saavalainen P, Sands B, Sartor RB, Schiff ER, Schreiber S, Schumm LP, Segal AW, Seksik P, Shawky R, Sheikh SZ, Silverberg MS, Simmons A, Skeiceviciene J, Sokol H, Solomonson M, Somineni H, Sun D, Targan S, Turner D, Uhlig HH, vanderMeulen AE, Vermeire S, Verstockt S, Voskuil MD, Winter HS, Young J, Duerr RH, Franke A, Brant SR, Cho J, Weersma RK, Parkes M, Xavier RJ, Rivas MA, Rioux JD, McGovern DPB, Huang H, Anderson CA, Daly MJ. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn's disease susceptibility. Nature Genetics 2022, 54, 1275-1283.
  • Pavlidis P, Tsakmaki A, Pantazi E, Li K, Cozzetto D, Digby-Bell J, Yang F, Lo JW, Alberts E, Sa ACC, Niazi U, Friedman J, Long AK, Ding Y, Carey CD, Lamb CA, Saqi M, Madgwick M, Gul L, Treveil A, Korcsmaros T, MacDonald TT, Lord GA, Bewick GA, Powell N. Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy. Nature Communications 2022, 13, 5820.
  • Hawthorne AB, Glatter J, Blackwell J, Ainley R, Arnott I, Barrett KJ, Bell G, Brookes MJ, Fletcher M, Muhammed R, Nevill AM, Segal J, Selinger CP, St Clair Jones A, Younge L, Lamb CA. Inflammatory Bowel Disease patient-reported quality assessment should drive service improvement: a national survey of UK IBD units and patients. Alimentary Pharmacology & Therapeutics 2022, 56(4), 625-645.
  • Ricciuto A, Lamb CA, Benchimol EI, Walker GJ, Kennedy NA, Kuenzig ME, Kaplan G, Kappelman MD, Ungaro RC, Colombel J-F, Brenner EJ, Agrawal M, Reinisch W, Griffiths AM, Sebastian S. Inflammatory Bowel Disease Clinical Activity Is Associated with COVID-19 Severity Especially in Younger Patients. Journal of Crohn's & Colitis 2022, 16(4), 591-600.
  • Lin S, Kennedy NA, Saifuddin A, Muñoz Sandoval D, Reynolds CJ, Castro Seoane R, Kottoor SH, Pieper FP, Lin K-M, Butler DK, Chanchlani N, Nice R, Chee D, Bewshea C, Janjua M, McDonald TJ, Sebastian S, Alexander JL, Constable L, Lee JC, Murray CD, Hart AL, Irving PM, Jones G-R, Kok KB, Lamb CA, Lees CW, Altmann DM, Boyton RJ, Goodhand JR, Powell N, Ahmad T. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in 1 inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications 2022, 13, 1379.
  • Sebastian S, Patel KV, Segal JP, Subramanian S, Conley TE, Gonzalez HA, Kent AJ, Saifuddin A, Hicks L, Mehta S, Bhala N, Brookes MJ, Lamb CA, Kennedy NA, Walker GJ. Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study. BMJ Open Gastroenterology 2022, 9, e000763.
  • Nelson A, Stewart CJ, Kennedy NA, Lodge JK, Tremelling M, Probert CS, Parkes M, Mansfield JC, Smith DL, Hold GL, Lees CW, Bridge SH, Lamb CA. The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn’s Disease Patients in Remission and Individuals Without Gastrointestinal Inflammation. Journal of Crohn's & Colitis 2021, 15(5), 800-812.
  • Alexander JL, Moran G, Gaya DR, Raine T, Hart A, Kennedy NA, Lindsay JO, MacDonald J, Segal JP, Sebastian S, Selinger S, Parkes M, Smith PJ, Dhar A, Subramanian S, Arasaradnam R, Lamb CA, Ahmad T, Lees C, Dobson L, Wakeman R, Arnott I, Powell N. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. The Lancet Gastroenterology and Hepatology 2021, 6(3), 218-224.
  • Lamb CA, Sebastian S, Kent AJ, Segal JP, Gonzalez HA, Brookes MJ, Mehta SJ, Subramanian S, Bhala N, Hicks LC, Conley TE, Patel KV, Walker GJ, Kennedy NA. Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications - reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study. Alimentary Pharmacology & Therapeutics 2021, 53(11), 1236-1240.
  • Keir ME, Fuh F, Ichikawa I, Acres M, Hackney J, Hulme G, Carey CD, Palmer J, Jones CJ, Long AK, Jiang J, Kablunde S, Mansfield JC, Looney M, Faubion WA, Filby A, Kirby JA, McBride J, Lamb CA. Regulation and role of αE integrin and gut homing integrins in migration and retention of intestinal lymphocytes during inflammatory bowel disease. The Journal of Immunology 2021, 207(7), ji2100220.
  • Mahalhal A, Frau A, Burkitt MD, Ijaz UZ, Lamb CA, Mansfield JC, Lewis S, Pritchard DM, Probert CS. Oral ferric maltol does not adversely affect the intestinal microbiome of patients or mice, but ferrous sulphate does. Nutrients 2021, 13(7), 2269.
  • Kennedy NA, Goodhand JR, Lin S, Chanchlani N, Bewshea C, Nice R, Chee D, Irving PM, Kok KB, Lamb CA, Verma A, Mehta SJ, Pollok RC, Raine T, Cummings JRF, Smith PJ, MacDonald J, Kamperidis N, Fraser A, McDonald TJ, Sebastian S, Lees CW, Powell N, Ahmad T. Infliximab and immunomodulators reduce the immunogenicity of a single dose of ChAdOx1 nCoV-19 and BNT162b2 SARS-CoV-2 vaccines. Gut 2021, 70(10), 1884-1893.
  • Din S, Gaya DR, Kammermeir J, Lamb CA, Macdonald J, Moran GW, Parkes G, Pollock R, Sebastian S, Segal JP, Selinger CP, Smith PJ, Steed H, Arnott ID. Inflammatory Bowel Disease Clinical Service Recovery during the COVID-19 Pandemic. Frontline Gastroenterology 2021, 31(1), 77-81.
  • Masi AC, Embleton ND, Lamb CA, Young G, Granger CL, Najera JA, Smith DP, Hoffman KL, Petrosino JF, Bode L, Berrington JE, Stewart CJ. Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis. Gut 2021, 70(12), 2273-2282.
  • Sebastian S, Walker GJ, Kennedy NA, Conley TE, Patel KV, Subramanian S, Kent AJ, Segal JP, Brookes MJ, Bhala N, Gonzalez HA, Hicks LC, Mehta SJ, Lamb CA. Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. The Lancet Gastroenterology and Hepatology 2021, 6(4), 271-281.
  • Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, Hart AL, Irving PM, Kok KB, Lamb CA, Limdi JK, Macdonald J, McGovern DPB, Mehta SJ, Murray CD, Patel KV, Pollok RCG, Raine T, Russell RK, Selinger CP, Smith PJ, Bowden J, McDonald TJ, Lees CW, Sebastian S, Powell N, Ahmad T. Anti-SARS-CoV2 antibody responses are attenuated in patients with inflammatory bowel disease treated with infliximab. Gut 2021, 70(5), 865-875.
  • Lamb CA, Parkinson D, Nylander D, Mountford CG. Enterobius vermicularis infection associated with positive faecal occult blood testing and eosinophilia. The Lancet Gastroenterology and Hepatology 2021, 6(6), 510-510.
  • Crouch LI, Liberato MV, Urbanowicz PA, Basle A, Lamb CA, Stewart CJ, Cooke K, Doona M, Needham S, Brady RR, Berrington JE, Madunic K, Wuhrer M, Chater P, Pearson JP, Glowacki R, Martens EC, Zhang F, Linhardt RJ, Spencer DIR, Bolam DN. Prominent members of the human gut microbiota express endo-acting O-glycanases to initiate mucin breakdown. Nature Communications 2020, 11(1), 4017.
  • Kennedy NA, Hansen R, Younge L, Mawdsley J, Beattie RM, Din S, Lamb CA, Smith PJ, Selinger CP, Limdi JK, Iqbal TH, Lobo A, Cooney R, Brain O, Gaya DR, Murray CD, Kent A, Raine T, Bhala N, Lindsay JO, Irving P, Lees CW, Sebastian S. Organisational changes and challenges for inflammatory bowel disease services in the United Kingdom during the COVID-19 pandemic. Frontline Gastroenterology 2020, 11(5), 343-350.
  • Jardine L, Cytlak U, Gunawan M, Reynolds G, Green K, Wang XN, Pagan S, Paramitha M, Lamb CA, Long A, Hurst E, Nair S, Jackson GH, Publicover A, Bigley V, Haniffa M, Simpson AJ, Collin M. Donor monocyte-derived macrophages promote human acute graft-versus-host disease. The Journal of Clinical Investigation 2020, 130(9), 4574-4586.
  • Kapasi R, Glatter J, Lamb CA, Acheson AG, Andrews C, Arnott I, Barrett KJ, Bell G, Bhatnagar G, Bloom S, Brookes MJ, Brown SR, Burch NE, Burman A, Crook KP, Cummings F, Davies RJ, Demick A, Epstein J, Faiz O, Feakins RM, Fletcher M, Garrick V, Jaffray B, Johnson M, Keetarut K, Limdi JK, Muhammed R, Murdock A, Posford N, Rowse G, Shaw IS, St Clair Jones A, Taylor SA, Weaver S, Younge L, Hawthorne AB. Consensus Standards of Healthcare for Adults and Children with Inflammatory Bowel Disease in the United Kingdom. Frontline Gastroenterology 2020, 11(3), 178-187.
  • Kennedy NA, Jones GR, Lamb CA, Appleby R, Arnott I, Beattie RM, Bloom S, Brooks AJ, Cooney R, Dart RJ, Edwards C, Fraser A, Gaya DR, Ghosh S, Greveson K, Hansen R, Hart A, Hawthorne AB, Hayee B, Limdi JK, Murray CD, Parkes GC, Parkes M, Patel K, Pollok R, Powell N, Probert C, Raine T, Sebastian S, Selinger CP, Smith PJ, Stansfield C, Younge L, Lindsay JO, Irving PM, Lees CW. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut 2020, 69(6), 984-990.
  • Din S, Kent A, Pollok R, Meade S, Kennedy N, Arnott I, Beattie R, Chua F, Cooney R, Dart R, Galloway J, Gaya D, Ghosh S, Griffiths M, Hancock L, Hansen R, Hart A, Lamb CA, Lees C, Limdi J, Lindsay J, Patel K, Powell N, Murray C, Probert C, Raine T, Selinger C, Sebastian S, Smith PJ, Tozer P, Ustianowski A, Younge L, Samaan M, Irving P. Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut 2020, 69(10), 1769-1777.
  • Stewart CJ, Fatemizadeh R, Parsons P, Lamb CA, Shady DA, Petrosino JF, Hair AB. Using formalin fixed paraffin embedded tissue to characterize the preterm gut microbiota in necrotising enterocolitis and spontaneous isolated perforation using marginal and diseased tissue. BMC Microbiology 2019, 19.
  • Thomas MG, Bayliss C, Bond S, Dowling F, Galea J, Jairath V, Lamb C, Probert C, Timperley-Preece E, Watson A, Whitehead L, Williams JG, Parkes M, Kaser A, Raine T. Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open 2019, 9, e023765.
  • Lamb CA, Mansfield JC, Kirby JA, Keir ME. The Importance of Molecular Immune Investigation in Therapeutic Clinical Development for Biomarker Assessment. Journal of Crohn's and Colitis 2019, 13(7), 956-957.
  • Swan DJ, Aschenbrenner D, Lamb CA, Chakraborty K, Clark J, Pandey S, Engelhardt KR, Chen R, Cavounidis A, Ding Y, Krasnogor N, Carey CD, Acres M, Needham S, Cant AJ, Arkwright PD, Chandra A, Okkenhaug K, Uhlig HH, Hambleton S. Immunodeficiency, autoimmune thrombocytopenia and enterocolitis caused by autosomal recessive deficiency of PIK3CD-encoded phosphoinositide 3-kinase δ. Haematologica 2019, 104(10), e483-e486.
  • Kirk C, Gemmell L, Lamb CA, Thompson NP, Mountford CG, Toole BJ. Elevated Whole-Blood Manganese Levels in Adult Patients Prescribed "Manganese-Free" Home Parenteral Nutrition. Nutrition in Clinical Practice 2019, 35(6), 1138-1142.
  • Lamb CA, Kennedy NA, Raine T, Hendy P, Smith PJ, Limdi JK, Hayee B, Lomer M, Parkes GC, Selinger CP, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop M, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson JD, Terry H, Gaya DR, Iqbal T, Taylor SA, Smith M, Brookes MJ, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019, 68(Suppl 3), s1-s106.
  • Kennedy NA, Lamb CA, Berry SH, Walker AW, Mansfield J, Parkes M, Simpkins R, Tremelling M, Nutland S, UK IBD Genetics Consortium, Parkhill J, Probert C, Hold GL, Lee CW. The Impact of NOD2 Variants on Fecal Microbiota in Crohn's Disease and Controls Without Gastrointestinal Disease. Inflammatory Bowel Diseases 2018, 24(3), 583-592.
  • Ichikawa R, Lamb CA, Eastham-Anderson J, Scherl A, Raffals L, Faubion WA, Bennett MR, Long AK, Mansfield JC, Kirby JA, Keir ME. AlphaE Integrin Expression Is Increased in the Ileum Relative to the Colon and Unaffected by Inflammation. Journal of Crohn's & Colitis 2018, 12(10), 1191-1199.
  • Schwerd T, Bryant RV, Pandey S, Capitani M, Meran L, Cazier J-B, Jung J, Mondal K, Parkes M, Mathew CG, Fiedler K, McCarthy DJ, Sullivan PB, Rodrigues A, Travis SPL, Moore C, Sambrook J, Ouwehand WH, Roberts DJ, Danesh J, Russell RK, Wilson DC, Kelsen JR, Cornall R, Denson LA, Kugathasan S, Knaus UG, Serra EG, Anderson CA, Duerr RH, McGovern DPB, Cho J, Powrie F, Li VSW, Muise AM, Uhlig HH, Donnelly P, Bell J, Bentley D, McVean G, Ratcliffe P, Taylor J, Wilkie AOM, Donnelly P, Broxholme J, Buck D, Cazier J-B, Cornall R, Gregory L, Gregory J, Lunter G, McVean G, Taylor J, Tomlinson I, Wilkie AOM, Buck D, Allan C, Attar M, Green A, Gregory L, Humphray S, Kingsbury Z, Lamble S, Lonie L, Pagnamenta A, Piazza P, Polanco G, Trebes A, McVean G, Donnelly P, Cazier J-B, Broxholme J, Copley R, Fiddy S, Grocock R, Hatton E, Holmes C, Hughes L, Humburg P, Kanapin A, Lise S, Lunter G, Martin H, Murray L, McCarthy D, Rimmer A, Sahgal N, Wright B, Yau C, Arancibia C, Bailey A, Barnes E, Bird-Lieberman B, Brain O, Braden B, Collier J, East J, Geremia A, Howarth L, Keshav S, Klenerman P, Leedham S, Palmer R, Powrie F, Rodrigues A, Simmons A, Sullivan PB, Travis SPL, Uhlig HH, Heuschkel R, Zilbauer M, Auth MKH, Shah N, Kammermeier J, Croft N, Barakat F, Russell RK, Wilson DC, Henderson P, Braegger CP, Posovszky C, Fyderek K, Wedrychowicz A, Zurek M, Strisciuglio C, Elawad M, Lo B, Parkes M, Satsangi J, Anderson CA, Jostins L, Kennedy NA, Lamb CA, Ahmad T, Edwards C, Hart A, Hawkey C, Mansfield JC, Mowat C, Newman WG, Satsangi J, Simmons A, Tremelling M, Uhlig HH, Wilson DC, Lee JC, Prescott NJ, Lees CW, Mathew CG, Parkes M, Barrett JC, Anderson CA. NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease. Mucosal Immunology 2018, 11(2), 562-574.
  • Embleton ND, Berrington JE, Dorling J, Ewer AK, Juszczak E, Kirby JA, Lamb CA, Lanyon CV, McGuire W, Probert CS, Rushton SP, Shirley MD, Stewart CJ, Cummings SP. Mechanisms Affecting the Gut of Preterm Infants in Enteral Feeding Trials. Frontiers in Microbiology 2017, 4, 14.
  • de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, Jostins L, Rice DL, Gutierrez-Achuryl J, Ji SG, Heap G, Nimmo ER, Edwards C, Henderson P, Mowat C, Sanderson J, Satsangi J, Simmons A, Wilson DC, Tremelling M, Hart A, Mathew CG, Newman WG, Parkes M, Lees CW, Uhlig H, Hawkey C, Prescott NJ, Ahmad T, Mansfield JC, Anderson CA, Barrett JC. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nature Genetics 2017, 49(2), 256-261.
  • Luo Y, de Lange KM, Jostins L, Moutsianas L, Randall J, Kennedy NA, Lamb CA, McCarthy S, Ahmad T, Edwards C, Serra EG, Hart A, Hawkey C, Mansfield JC, Mowat C, Newman WG, Nichols S, Pollard M, Satsangi J, Simmons A, Tremelling M, Uhlig H, Wilson DC, Lee JC, Prescott NJ, Lees CW, Mathew CG, Parkes M, Barrett JC, Anderson CA. Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. Nature Genetics 2017, 49(2), 186-192.
  • Lamb CA, Mansfield JC, Tew GW, Gibbons D, Long AK, Irving P, Diehl L, Eastham-Anderson J, Price MB, O'Boyle G, Jones DEJ, O'Byrne S, Hayday A, Keir ME, Egen JG, Kirby JA. aEß7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis. Journal of Crohn's and Colitis 2017, 11(5), 610-620.
  • Kennedy NA, Warner B, Johnston EL, Flanders L, Hendy P, Ding NS, Harris R, Fadra AS, Basquill C, Lamb CA, Cameron FL, Murray CD, Parkes M, Gooding I, Ahmad T, Gaya DR, Mann S, Lindsay JO, Gordon J, Satsangi J, Hart A, McCartney S, Irving P, UK Anti-TNF withdrawal study group, Lees CW. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Alimentary Pharmacology & Therapeutics 2016, 43(8), 910-923.
  • Dyson JK, Rajasekhar P, Wetten A, Hamad AH, Ng S, Paremal S, Baqai MF, Lamb CA, Masson S, Hudson M, Dipper C, Cowlam S, Hussaini H, McPherson S. Implementation of a “care bundle” improves the management of patients admitted to hospital with decompensated cirrhosis. Alimentary Pharmacology and Therapeutics 2016, 44(10), 1030–1038.
  • Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, Diehl L, Anderson JE, Vermeire S, Mansfield JC, Feagan BG, Panes J, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Kirby JA, Irving PM, De Hertogh G, Van Assche GA, Rutgeerts P, O'Byrne S, Hayday A, Keir ME. Association Between Response to Etrolizumab and Expression of Integrin alpha E and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. Gastroenterology 2016, 150(2), 477-487.e9.
  • Rivas MA, Graham D, Sulem P, Stevens C, Desch AN, Goyette P, Gudbjartsson D, Jonsdottir I, Thorsteinsdottir U, Degenhardt F, Mucha S, Kurki MI, Li D, D'Amato M, Annese V, Vermeire S, Weersma RK, Halfvarson J, Paavola-Sakki P, Lappalainen M, Lek M, Cummings B, Tukiainen T, Haritunians T, Halme L, Koskinen LLE, Ananthakrishnan AN, Luo Y, Heap GA, Visschedijk MC, MacArthur DG, Neale BM, Ahmad T, Anderson CA, Brant SR, Duerr RH, Silverberg MS, Cho JH, Palotie A, Saavalainen P, Kontula K, Farkkila M, McGovern DPB, Franke A, Stefansson K, Rioux JD, Xavier RJ, Daly MJ, Barrett J, De Lane K, Edwards C, Hart A, Hawkey C, Jostins L, Kennedy N, Lamb C, Lee J, Lees C, Mansfield J, Mathew C, Mowatt C, Newman B, Nimmo E, Parkes M, Pollard M, Prescott N, Randall J, Rice D, Satsangi J, Simmons A, Tremelling M, Uhlig H, Wilson D, Abraham C, Achkar JP, Bitton A, Boucher G, Croitoru K, Fleshner P, Glas J, Kugathasan S, Limbergen JV, Milgrom R, Proctor D, Regueiro M, Schumm PL, Sharma Y, Stempak JM, Targan SR, Wang MH. A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. Nature Communications 2016, 7, 12342.
  • Dyson JK, Elsharkawy AM, Lamb CA, Al-Rifai A, Newton JL, Jones DE, Hudson M. Fatigue in primary sclerosing cholangitis is associated with sympathetic over-activity and increased cardiac output. Liver International 2015, 35(5), 1633-1641.
  • Kennedy NA, Kalla R, Warner B, Gambles CJ, Musy R, Reynolds S, Dattani R, Nayee H, Felwick R, Harris R, Marriott S, Senanayake SM, Lamb CA, Al-Hilou H, Gaya DR, Irving PM, Mansfield J, Parkes M, Ahmad T, Cummings JRF, Arnott ID, Satsangi J, Lobo AJ, Smith M, Lindsay JO, Lees CW. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Alimentary Pharmacology & Therapeutics 2014, 40(11-12), 1313-1323.
  • Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Tew GW, Luca D, Tang MT, Diehl L, Eastham-Anderson J, De Hertogh G, Perrier C, Egen JG, Kirby JA, van Assche G, Rutgeerts P. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014, 384(9940), 309-318.
  • Douglass A, Meeson AP, Overbeck-Zubrzycka D, Brain JG, Bennett MR, Lamb CA, Lennard TWJ, Browell D, Ali S, Kirby JA. Breast cancer metastasis: demonstration that FOXP3 regulates CXCR4 expression and the response to CXCL12. The Journal of Pathology 2014, 234(1), 74-85.
  • Lamb CA, Lamb EIM, Mansfield JC, Sankar KN. Sexually transmitted infections manifesting as proctitis. Frontline Gastroenterology 2013, 4(1), 32-40.
  • Lamb CA, Reddy AV. Rifaximin for recurrent hepatic encephalopathy following transjugular intrahepatic portosystemic shunt insertion. Clinical Medicine 2012, 12(5), 489-490.
  • Lamb CA, Barbour JA. Developing an endoscopic mucosal resection service in a district general hospital. Frontline Gastroenterology 2012, 3, 272-277.
  • O'Boyle G, Fox CR, Walden HR, Willet JD, Mavin ER, Hine DW, Palmer JM, Barker CE, Lamb CA, Ali S, Kirby JA. Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation. Proceedings of the National Academy of Sciences 2012, 109(12), 4598-4603.
  • Lamb CA, Mansfield JC. Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease. Frontline Gastroenterology 2011, 2, 13-18.
  • Lamb CA. Gastroenterology 2010: Maximising patient care and safety while minimising unnecessary cost. Journal of the Royal College of Physicians of Edinburgh 2011, 41, 57-58.
  • Kanakala V, Lamb CA, Haigh C, Stirling RW, Attwood SE. The diagnosis of primary eosinophilic oesophagitis in adults: missed or misinterpreted?. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY 2010, 22(7), 848-855.
  • Lamb CA, Speight RA, Needham S, Graham JY, Mansfield JC. Management of Crohn's disease. GUT 2010, 59(3), 340-340.
  • Lamb CA, Kanakala V, Stirling RW, Attwood SEA. Clinical lesson: eosinophilic oesophagitis, a new diagnosis to swallow. Frontline Gastroenterology 2010, 1(1), 25-29.
  • Lewis CJ, Lamb CA, Kanakala V, Pritchard S, Armstrong GR, Attwood SEA. Is the etiology of eosinophilic esophagitis in adults a response to allergy or reflux injury? Study of cellular proliferation markers. DISEASES OF THE ESOPHAGUS 2009, 22(3), 249-255.
  • Lamb CA, Mohiuddin MK, Gicquel J, Neely D, Bergin FG, Hanson JM, Mansfield JC. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. British Journal of Surgery 2009, 96(6), 663-674.
  • Dipper CR, Maitra S, Thomas R, Lamb CA, McLean-Tooke APC, Ward R, Smith D, Spickett G, Mansfield JC. Anti-tissue transglutaminase antibodies in the follow-up of adult coeliac disease. Alimentary Pharmacology and Therapeutics 2009, 30(3), 236-244.
  • Lamb CA, Parr J, Lamb EI, Warren MD. Adult malnutrition screening, prevalence and management in a United Kingdom hospital: Cross-sectional study. British Journal of Nutrition 2009, 102(4), 571-5.
  • Attwood SEA, Lamb CA. Eosinophilic oesophagitis and other non-reflux inflammatory conditions of the oesophagus: Diagnostic imaging and management. Best Practice and Research: Clinical Gastroenterology 2008, 22(4), 639-660.

• Editorials

  • Hawthorne AB, Lamb CA. Editorial: quality assessment in IBD in high resource countries can lead to quality improvement clues for IBD management worldwide—authors' reply. Alimentary Pharmacology & Therapeutics 2022, 56(4), 743-743.
  • Lamb CA, Kirby JA. Donor intravascular monocyte trafficking: A potential therapeutic target for primary graft dysfunction following lung transplantation?. Thorax 2018, 73(4), 303-304.

• Letters

  • Masi AC, Fofanova TY, Lamb CA, Auchtung JM, Britton RA, Estes MK, Ramani S, Cockell S, Coxhead J, Embleton ND, Berrington JE, Petrosino JF, Stewart CJ. Distinct gene expression profiles between human preterm- and adult-derived intestinal organoids exposed to Enterococcus faecalis: A pilot study. Gut 2022, 71(10), 2141-2143.
  • Masi AC, Koo S, Lamb CA, Hull MA, Sharp L, Nelson A, Hampton JS, Rees CJ, Stewart CJ. Using faecal immunochemical test (FIT) undertaken in a national screening programme for large-scale gut microbiota analysis. Gut 2021, 70(2), 429-431.
  • Segal JP, Kumar A, Raine T, Lamb CA, Brookes MJ. The impact of SARS-CoV-2 variants on IBD management. The Lancet Gastroenterology and Hepatology 2021, 6(5), 343-344.
  • Masi AC, Oppong YEA, Haugk B, Lamb CA, Sharp L, Shaw JM, Stewart CJ, Oppong KW. Endoscopic ultrasound (EUS) guided fine needle biopsy (FNB) formalin preserved paraffin embedded (FFPE) pancreatic tissue samples are a potential resource for microbiota analysis. Gut 2021, 70(5), 999-1001.
  • Lamb CA. What’s in a name?. British Medical Journal 2009, 338, b2389.

• Reviews

  • Williams KC, Gault A, Anderson AE, Stewart CJ, Lamb CA, Speight RA, Rajan N, Plummer R, Pratt AG. Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations. Frontiers in Immunology 2023, 14, 1122430.
  • Lamb CA, Saiffuddin MA, Powell N, Rieder F. The future of precision medicine to predict outcomes and control tissue remodeling in inflammatory bowel disease. Gastroenterology 2022, 162(5), 1525-1542.
  • Wyatt N, Speight RA, Stewart CJ, Kirby JA, Lamb CA. Targeting leukocyte trafficking in inflammatory bowel disease. BioDrugs 2021, 35, 473-503.
  • Dart RJ, Ellul P, Scharl M, Lamb CA. Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD – Challenges and Future Directions. Journal of Crohn's & Colitis 2021, 15(9), 1407-1409.
  • Granger CL, Embleton ND, Palmer JM, Lamb CA, Berrington JE, Stewart CJ. Maternal breastmilk, infant gut microbiome and the impact on preterm infant health. Acta Paediatrica 2021, 110(2), 450-457.
  • Lamb CA, O'Byrne S, Keir ME, Butcher EC. Gut-selective integrin-targeted therapies for inflammatory bowel disease. Journal of Crohn's and Colitis 2018, 12(suppl. 2), S653-S668.